Intervertebral disc degeneration is strongly associated with chronic low back pain, a leading cause of disability worldwide. Current back pain treatment approaches (both surgical and conservative) are limited to addressing symptoms, not necessarily the root cause. Not surprisingly therefore, long-term efficacy of most approaches is poor. Cell-based disc regeneration strategies have shown promise in preclinical studies, and represent a relatively low-risk, low-cost, and durable therapeutic approach suitable for a potentially large patient population, thus making them attractive from both clinical and commercial standpoints. Despite such promise, no such therapies have been broadly adopted clinically. In this perspective we highlight primary obstacles and provide 
Intervertebral disc degeneration is strongly associated with chronic low back pain, a leading cause of disability worldwide. Current back pain treatment approaches (both surgical and conservative) are limited to addressing symptoms, not necessarily the root cause. Not surprisingly therefore, long-term efficacy of most approaches is poor. Cell-based disc regeneration strategies have shown promise in preclinical studies, and represent a relatively low-risk, low-cost, and durable therapeutic approach suitable for a potentially large patient population, thus making them attractive from both clinical and commercial standpoints. Despite such promise, no such therapies have been broadly adopted clinically. In this perspective we highlight primary obstacles and provide recommendations to help accelerate successful clinical translation of cell-based disc regeneration therapies. The key areas addressed include: (a) Optimizing cell sources and delivery techniques; 
| INTRODUCTION
Lower back pain is a leading cause of disability worldwide and the third most expensive health condition in the United States, with estimated health care spending in excess of $80 billion annually. 1, 2 It is a significant epidemiological and socioeconomic problem affecting quality of life, and is the most common, non-cancer reason for opioid prescription in the United States. 3 Intervertebral disc degeneration is a progressive, cell-mediated cascade of molecular, structural and biomechanical changes, which is strongly implicated as a cause of "discogenic" back pain. 4 The incidence of disc degeneration is linked to aging, trauma, genetics, lifestyle and the presence of comorbidities. [5] [6] [7] [8] [9] The intervertebral discs are the pliant, fibrocartilaginous joints required for transferring compressive loads and supporting complex mobility of the spine. 10 Each disc is comprised of a central, proteoglycan-rich, gelatinous nucleus pulposus (NP), a peripheral, fibrocartilaginous annulus fibrosus (AF), and superiorly and inferior, hyaline cartilage end plates that interface with the vertebral bodies. 10 The earliest degenerative changes typically manifest in the NP, where reductions in proteoglycan content and hydration compromise biomechanical function, leading to progressive degeneration of the entire intervertebral joint. 11, 12 Self-repair and regeneration of the NP is limited by a low cell density and a limited nutrient supply. 13, 14 Conventional treatments for disc degeneration are focused solely on alleviation of symptoms and often have limited long-term efficacy. [15] [16] [17] This is exacerbated by the lack of an accepted clinical standard for discogenic pain, where clinicians are often unable to identify a specific nociceptive cause. 18, 19 Because of this, the rationale for choosing surgery for these patients is controversial. Spinal fusion does not restore natural biomechanical function and has been shown to induce adjacent segment pathology (ASP) caused by increased mechanical stress in adjacent segments. 20 More specifically, in a study comparing 725 lumbar fusion cases to 725 randomly selected controls with chronic low back pain diagnoses, focusing on the outcome return to work (RTW) revealed only 26% of patients had RTW 2 years after fusion surgery, while 67% of nonsurgical controls had RTW within 2 years from the date of injury. 21 In addition, of the patients receiving spinal fusion, 36% had complications and the reoperation rate was 27%, with 66% of the reoperations occurring within 2 years of the index surgery. Of the 36% of complications, failed and/or implant malposition represented 4.7% of cases, while late spinal complications such as disc space infection, pseudarthrosis, postlaminectomy syndrome, adjacent disc degeneration, stenosis, spondylolisthesis, and adjacent vertebral fracture represented 25.2% of cases, with the balance relating to early major systemic, neurologic and wound complications.
There is therefore a tremendous unmet need for new treatment options for patients with disc degeneration and associated lower back pain. To address this need, there has been significant recent interest in developing injectable cell-based therapies for the treatment of disc degeneration with the specific aim to stimulate tissue repair. 22 Such therapies represent a potentially low risk and low cost long term solution for a very large patient population, making them attractive from both clinical and commercial standpoints. Schol reported cell numbers ranging from 1 to 40 million cells being used in investigations. 55 It is postulated that the delivery of large numbers of cells may exacerbate the degenerative microenvironment due to competing nutrient demands, which may in turn result in ineffective clinical outcomes. 56 Given the varying stages of degeneration and microenvironments that exist in vivo, it will be important to tailor or design treatments for individuals. One way to achieve this could be to condition stem cells prior to implantation by acclimatizing them to patient specific in vivo microenvironmental milieu, which may include inflammatory cytokines, acidity, oxygen or nutrient deprivation. [57] [58] [59] These treatments must be assessed using appropriate in vitro and ex vivo culture conditions which mimic those of the degenerate niche to assess the likely behavior and survival of transplanted cells prior to progressing to in vivo testing. 49 
| Primary cells, stem cells or gene therapy?
From a surgical and practical perspective, given the unique structure and location of the disc, the difficulty in obtaining autologous primary NP tissue and cells for therapeutic use from either herniated discs or adjacent intact levels is clear. Delivery of primary NP cells to the disc appears safe and has shown some potential for efficacy in early clinical trials. 60 Additional limitations of primary cells include the diminished tissue forming capacity of culture expanded NP cells derived from degenerated tissue 26 and the altered catabolic phenotype of such cells, together with the paucity of NP cells that can be isolated.
Furthermore, the isolation of tissue from adjacent healthy disc levels may increase the risk of initiating degeneration at the harvest site.
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This has motivated many researchers into identifying and characterizing alternative cell sources for disc regeneration, which is a key step towards translating therapies into clinical practice. 62 Primary, differentiated cells from other skeletal sites with reduced risk for donor site morbidity, such as articular and nasal cartilage, have been investigated in vitro and in animal models for NP regeneration. [63] [64] [65] While these cell types do exhibit some phenotypic differences to native NP cells, their relative ease of isolation, differentiated state and higher propensity to deposit extracellular matrix may make them attractive alternatives in the future and warrant further consideration and exploration.
The likelihood that these alternative cell types can adopt a true discogenic phenotype is remote, and whether the extracellular matrix constituents they deposit are suitable to provide biomechanical functionality and longevity to restore disc function remains to be fully established.
Stem cell therapies have received considerable attention due to their versatility, translatability and potential for long term native tissue regeneration. Some successful patient outcomes have been demonstrated in clinical studies using this approach. 28, 29, 55, [66] [67] [68] The bone marrow has been the prime site of MSC isolation for disc regeneration applications, inclusive of in vitro, preclinical and clinical studies. 61, 69 Progenitor cells derived from other tissue sources such as adipose tissue have also been shown to possess significant potential for differentiation and tissue forming capabilities. 70, 71 Adipose derived stem cells (ADSCs) may provide a better alternative and candidate for cell therapy and disc regeneration, due to their abundance and ease of isolation, and may also have a lower inherent capacity than bone marrow derived MSCs to undergo endochondral ossification. 72 Harvesting of autologous ADSCs can be performed in outpatient clinics with typical yields of up to 25 000 adherent ADSCs per gram of tissue. 73 One of the potential challenges in utilizing stem cells is that they are undiffer- Gene therapy approaches may hold significant promise for disc regeneration, for example through silencing of catabolic or activating anabolic pathways. Gene therapy has advantages over direct delivery of proteins or small molecules, among them the possibility of sustained efficacy through long-term, regulated, endogenous synthesis of growth factors or anti-inflammatory factors. 78 However, the need to establish a safety profile and possible off target effects will most likely lead to a longer and more complex regulatory process before realizing a commercially available product and clinical translation.
| Effective cell delivery and retention
With respect to delivery of cell-based therapies, the primary mode of choice has been injection through the AF. A key translational advantage of this approach is that, with image-guided assistance, it can be performed percutaneously. However, there are associated challenges that have the potential to compromise both safety and efficacy, including the potential for needles to induce permanent AF damage, 79 cell leakage from the delivery site and diminished cell viability due to shear forces as cells are forced through small diameter needles. [80] [81] [82] For example, injecting a cell suspension into the lumbar discs of rabbits resulted in a 90% loss of the injected cells within the first 30 minutes. 83 Biomaterials as delivery vehicles, and in particular hydrogels, have been utilized to overcome retention issues and provide additional support for cell survival and phenotype retention. [84] [85] [86] [87] [88] [89] Injectable biomaterial systems utilizing alginates, collagens, hyaluronic acid, fibrin and a variety of other substances have all shown promise for improving cell delivery for disc repair [90] [91] [92] ; however, for clinical translation, the biomaterial itself will require regulatory approval.
Using biomaterials already approved and in clinical use for other indications may accelerate the approval process. That being said, because the disc is avascular, carrier degradation products may accumulate to levels beyond those found in other target tissues, justifying discspecific toxicity testing. Selection of needle size for trans-annular delivery should be a careful trade-off between the minimum size necessary to prevent shear-induced cell death and allow injection of viscous hydrogels, and the maximum size necessary to prevent permanent AF damage and/or cell leakage. In a recent study using a preclinical large frame goat model, a 22G needle was found not to induce discernable degenerative changes on MRI or histology after 12 weeks. 93 In addition, the volume to be delivered needs to be optimized, as excessive volumes may result in over pressurization, increasing the likelihood of cell leakage upon needle withdrawal. Further, the spatial distribution of delivered cell populations may also impact cell differentiation or activity and subsequent regeneration outcomes, as injected materials will tend to preferentially concentrate within preexisting fissures that are common in degenerated discs. For hydrogeldelivered cell populations, migration of cells through the NP and integration of the injected material with native tissue should be considered. An alternative delivery route that has been investigated, and which does not cause disruption to the AF, is through the pedicles/ endplates (transpedicular approach); 94, 95 however, whether such an approach will have detrimental effects to the integrity of the endplate in the long term is yet to be established.
| MINIMIZING POTENTIAL RISKS TO PATIENTS
Demonstrating safety is critical for disc therapies, as the consequences of an adverse event are potentially severe. The disc is one of the most highly loaded tissues in the body, which creates the significant potential that injected biomaterials will migrate in response to long term, cyclic loading. Material that is expelled from the disc space may impinge on nerves and result in neurological complications or even paralysis. Therefore, a fundamental safety requirement of a disc therapy, particularly one that involves a structural component such as a hydrogel or scaffold, is that it structurally integrates, and remains completely and permanently contained within the disc space upon 97 Minimizing the length of culture and degree of cellular manipulation prior to implantation minimizes the propensity for these in vitro genetic alterations to occur. Assessing the heterogeneity of stem cell populations in culture is also important to reduce tumorigenic and immunogenic risk.
Gene therapy, which employs cellular reprogramming, poses unique safety challenges that may limit or complicate translatability. 100 These risks, which include the potential for insertional muta- for painful disc degeneration is long term (>6 months) alleviation of symptoms. Current treatment strategies, whether they be conservative or surgical, may be effective in providing short term relief from pain, but their long-term efficacy is more problematic, in part because they do not seek to restore disc structure or mechanical function.
Given the nature of disc degeneration and its cascading effect on adjacent tissues and overall spine mechanical properties, it is often difficult to specify the fundamental treatment target. Disruption of normal disc biomechanical properties is associated with accelerated degeneration of other structures such as facet joints, and osteophyte formation due to adaptive bony changes or calcification of ligaments. 102 For cell therapies to be clinically adopted, they need to demonstrate benefits beyond current treatment options. The rationale for choosing between surgical and nonsurgical care for chronic low back pain patients is not well-defined. While the benefit of surgery for "mechanical" back pain (such as instability and sciatica) is supported by significant outcome literature, the appropriate intervention for disc-related pain is less clear. Fusion surgery may alleviate pain by restoring intervertebral height and decompressing nerves, but immobilizes the intervertebral joint. 15, 17 Metal/polymer-based total disc arthroplasties preserve a limited degree of joint mobility, but are subject to wear and potential failure requiring revision surgery, and have not seen widespread adoption. 108 Reported success of surgical care
for back pain ranges from 41% to 57%, 109 and with 5% to 16% early complication and reoperation rates. 110 Discectomy may alleviate symptoms by removing herniated or bulging disc material and decompressing nerves, but the damaged disc is not repaired and may continue to degenerate, and many patients continue to experience pain and require ongoing treatment. 111 Non-surgical approaches such as steroid injections and physical therapy are temporary treatments that seek to mask symptoms that might otherwise resolve over time.
Recurrent treatment for unresolving symptoms is more problematic as permanent nerve damage can occur. Non-surgical, like surgical, treatment does not alter the long term progression of degeneration. Restoration of disc biomechanical function is therefore key to effective long-term alleviation of painful symptoms.
The primary attraction of biological, cell-based disc regeneration therapies is that they have the potential to alleviate symptoms and Outcome measures for in vitro, in vivo preclinical, and clinical evaluation of such therapies should be selected with these goals in mind. inflammatory stimuli compared to endogenous cells. [114] [115] [116] For in vitro cell culture models, mimicking this in vivo disc microenvironment can be accomplished by culturing cells in low oxygen, and reduced glucose and serum, to simulate nutrient deprivation. [115] [116] [117] The degenerate environment can be further simulated by including catabolic mediators such as inflammatory cytokines and by increasing acidity. [118] [119] [120] The physical environment can be mimicked through culturing in soft 3D scaffolds such as hydrogels. Mechanical stress can be simulated using bioreactors that apply dynamic compressive loads and/or hydrostatic pressure. [121] [122] [123] [124] Organ culture systems that employ living, degenerate discs from human donors may be the ultimate platform to effectively mimic the biological complexity of the in vivo cellular microenvironment, particularly when combined with a bioreactor that applies physiological loading. 125 Ensuring accurate recapitulation of the human disc cellular microenvironment is equally important when moving to in vivo systems.
| Appropriate selection and implementation of model systems to demonstrate efficacy
One of the greatest challenges facing in vivo models of disc therapeutics is the need to replicate the size, and in particular the height of the human disc, necessary to accurately recapitulate physiological nutritional demands. Large animals obviously more closely approximate the nutritional environment compared to rodents, however, even in livestock, lumbar disc size is still significantly smaller than in humans (eg, lumbar disc height in sheep is~4 mm compared to~11 mm in humans). For example, a surgeon performing a procedure such as a spinal fusion may be able to provide not only surgical waste tissue as a source of endogenous disc cells, but also bone marrow from the adjacent vertebrae without subjecting the patient to any additional surgical procedures or risks. As already discussed, organ culture using degenerate human discs obtained from cadavers represents an avenue for evaluating therapeutic efficacy not only using human cells, but also in a physiologically accurate and degenerative microenvironment. The importance of cell source also extends to the preclinical development phase. For example, a therapy that demonstrates efficacy in vitro using cells of a particular age and species, may not demonstrate similar efficacy in a large animal model of a different age and species. In vitro studies should therefore seek to validate a therapeutic approach using cells from the full range of sources that will be required at each phase of development.
| Pain and disability outcome measures
As alleviation of pain is the primary goal of disc therapies, including pain as an outcome measure in laboratory experiments is desirable.
Selection of physiologically-relevant pain outcome measures in the preclinical setting is complicated, as in the clinical setting pain is subjective and its direct source may be ill-defined. 131, 132 Pain outcome measures can be classified in different ways. They may include surrogates such as nerve ingrowth and regression, 133, 134 local and systemic levels of secreted neurogenic and inflammatory factors, 135, 136 as well as imaging to demonstrate nerve compression. 45 Direct outcome measures of pain may include assessments of overall behavior and mobility, and pain sensitivity assays. 137 Small animal models are particularly attractive with respect to assessing pain, as they are compatible with most if not all of these outcome measure types. For example, if a therapy is being evaluated in a mouse or rat, it is possible and practical to assess mobility, pain sensitivity, and serum and radiological biomarkers in vivo, and tissue level expression of neurogenic markers post mortem. Using in vitro models, pain outcomes are limited to surrogates such as expression of neurogenic factors and nerve ingrowth. Large animal models are in theory compatible with many of the same outcome measures as small animal models, but practical considerations make implementation of functional and pain sensitivity assays more challenging.
| Structural and biomechanical outcome measures
Including appropriate outcome measures to assess restoration of disc structure and mechanical function is equally important, as these are the key indicators of the likelihood for a therapy to provide long term alleviation of symptoms. Like pain, the ability to assess these parameters directly or indirectly is dependent on the type of model system.
With respect to structure, the most clinically relevant outcome measure is stabilization or restoration of disc height as demonstrated through imaging (MRI, plain radiographs or computed tomography), and is possible for in vivo models as well as in vitro whole-disc organ culture models. 93, 138, 139 Importantly, these non-invasive imaging metrics can be applied longitudinally and thus used to confirm both acute regenerative effects and sustained, long term efficacy. With respect to biomechanical properties, in vitro model systems that incorporate three-dimensional constructs or whole-disc organ culture facilitate direct assessment of mechanical function. 89, 140 For in vivo models, mechanical properties can be assessed ex vivo on intact spinal motion segments or isolated tissue samples. 85 In the case of motion segments, multi-axis loads can be applied to similar physiological deformations, including those likely to lead to failure. 141 Direct, in vivo evaluation of disc mechanical properties is possible using emerging technologies such as magnetic resonance elastography. Other factors should be considered and continuously reviewed as the concept evolves, including complexity, cost of components and preparation time, in addition to the ease and method of administration.
Early and frequent discussions with regulators (eg, FDA) are key to defining the studies required to translate such products into the clinic, and to ensure that manufacturing approaches will meet the standards required for human testing.
One predictor of the potential commercial viability of a new therapy is the size of the prospective target patient population. Further, the overall manufacturing costs associated with producing the product, in contrast to the reimbursement/pricing potential of the treatment, must be favorable. In considering the clinical motivation for developing a specific biological disc therapy, the overall socioeconomic burden is often cited, as is the current lack of effective treatment options. In establishing and justifying the clinical need for a specific, new therapeutic approach, it is necessary to move beyond general patient populations (ie, "degenerative disc disease") and stratify subgroups of patients that will be suitable candidates for that therapeutic approach based on the specific disease features experi- For first or second generation therapeutic products, investigators should also be cognizant and take steps at an early stage to avoid developing "complex" approaches, which will most likely face signifi- 
| THE IMPORTANCE OF MULTIDISCIPLINARY COLLABORATION AND ENGAGING WITH CLINICIANS
Closely linked to commercial viability and prospective market uptake is the willingness of clinicians to embrace the newly developed therapeutic approach. There may be resistance within a particular market sector to switch away from traditional treatment approaches, for example, for philosophical, financial or logistical reasons. To ensure a new disc therapy will successfully and effectively translate from the lab to the clinic, basic scientists must therefore work to ensure that the new product will ultimately be enthusiastically embraced by those clinicians required to administer it. To achieve this, it is essential to engage clinicians early and continuously from inception through to translation, and these clinical collaborators may well already be passionate about identifying novel treatment strategies for their low back pain patients. Not only will the participation of clinicians (as the end users) aid market acceptance, it will also add significant value to the overall scientific endeavor. In the early stages, clinicians will be able to draw on their extensive, firsthand experience to help identify prospec- Recommendations for researchers to effectively address these challenges are provided, falling broadly under the key themes of "Safety, Efficacy, Commercial Viability and Engaging Clinicians" (summarized in Table 1 ). The authors urge researchers to consider and leverage these recommendations to enhance the translational relevance and clinical potential of their research endeavors and activities. • Demonstrate long term retention in the disc space under physiological loading
• Select experimental outcomes relevant to the overall goal of long term alleviation of symptoms through stabilization/ restoration of disc structure and biomechanical function
• Identify the size of the prospective target patient population
• Engage clinicians early and continuously during development
• Evaluate acute and chronic, local and systemic toxicity in vitro and in vivo, and include effects of degradation products
• Apply model systems iteratively, balancing experimental control, cost and throughput in the early stages with biological complexity and clinical relevance at more advanced stages
• Protect intellectual property early by submitting an invention disclosure to the relevant university office
• Anticipate resistance to switching away from current therapeutic approaches
• Minimally invasive delivery carries less risk than an open surgical approach
• Design model systems to appropriately mimic aspects of the in vivo chemical, physical and mechanical microenvironments of the disc
• Minimize cost and complexity with respect to production, preparation and administration
• Clinicians can provide primary human sourced material for in vitro testing, and develop and refine techniques for in vivo modeling and therapeutic administration
• Aim for a single administration vs multiple administrations
• Consider the confounding effects of species, age and sex on efficacy in vitro and in animal models
• Minimize the number of potential regulatory hurdles
• Clinicians can advise and lead design and implementation of clinical trials, including patient recruitment
• Maximize genetic stability of stem cell therapies by minimizing in vitro manipulation
• Incorporate human-sourced cells and tissues into experiments
• Undertake a comprehensive survey of the competitive landscape
• Clinicians can advocate new therapeutic approaches to patients and health systems, accelerating their early and widespread adoption
• Autologous cell therapies pose less of a risk than allogeneic
• Where outcomes such as pain or mechanical properties cannot be measured directly, carefully justified, clinically relevant surrogates should be used
• Clinicians can facilitate dissemination and promotion of new therapeutic approaches to colleagues at clinical scientific meetings
• Clearly define success benchmarks for all experimental outcomes Dr Buckley was supported by Science Foundation Ireland Career
